- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00932607
SUBLIVAC® Birch PROBE Study
SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hessen
-
Wiesbaden, Hessen, Germany, D-65183
- Zentrum für Rhinologie & Allergologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with allergic rhinoconjunctivitis with or without mild asthma (FEV1 ≥ 70%) due to birch pollen for at least 2 years.
- Use of anti-allergy symptomatic medication in the last birch pollen season (in case of a season with low pollen counts, in one of the two previous years).
- No seasonal allergic complaints induced by birch, grasses or mugwort pollen for at least 4 weeks in the absence of rescue medication during at least the last 2 weeks before the baseline.
- A positive SPT (diameter ≥3 mm) for birch pollen and a positive specific serum anti birch IgE-test (>1 U/ml).
- A positive TNPT with a birch allergen extract containing a concentration of 10, 100 or 1000 AU/ml at the baseline visit.
- Age 18 years and older.
- Subjects shall give a written informed consent.
Exclusion Criteria:
- A positive SPT (diameter ≥ 3mm) for hazel or alder and the maintenance dose will not be reached before 8 October 2009.
- A positive SPT (diameter ≥ 3mm) for pets and symptoms related to concomitant sensitization to pets while having these animals at home.
- A positive SPT (diameter ≥ 3mm) for house dust mite or moulds and clinically relevant symptoms related to concomitant sensitization to house dust mite or moulds, based on the investigator's research (TNPT for example).
- Allergy to any of the excipients of SUBLIVAC Birch or Staloral Birch.
- Chronic asthma or emphysema, particularly with an FEV1 < 70 % of predicted value or use of inhalation corticosteroids outside grass and tree pollen season for more than two episodes and/or longer than fourteen days.
- Specific findings for nose and mouth at screening or rhinoscopy before TNPT.
- Serious immuno-pathological diseases or malignancies (including auto-immune diseases, tuberculosis, HIV).
- Inflammation or infection of the target organ (nose, eyes and lungs).
- Severe atopic dermatitis requiring systemic immuno-suppressive medication.
- Allergen specific immunotherapy treatment for a period longer than 3 months within the last 5 years.
- History of life threatening anaphylactic events, including anaphylactic food allergy, insect venom anaphylaxis, exercise or drug induced anaphylaxis.
- A positive pregnancy test, lactation or inadequate contraceptive measures. (adequate measures: oral contraceptives, IUD, condom use and having no sexual relationship with a man)
- Alcohol- or drug abuse.
- Lack of co-operation or severe psychological disorders.
- Completed or ongoing long-term treatment with tranquilizer or psycho active drugs.
- Low compliance or inability to understand instructions/study documents
- Completed or ongoing treatment with anti-IgE-antibody
- Patients being in any relationship or dependence with the sponsor or investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Staloral Birch
Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken. Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy). |
Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken. Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed. Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy). |
Experimental: SUBLIVAC Birch
Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy). |
Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken. Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed. Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in change of the titrated nasal provocation test (TNPT) between the two treatment groups
Time Frame: 16-20 weeks of treatment
|
16-20 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunoglobulins, changes in TNPT derived variables
Time Frame: 16-20 weeks of treatment
|
16-20 weeks of treatment
|
Determination of specific IgE and specific IgG to birch at the baseline and the end of study. It is expected that changes in specific IgE and IgG will be equal in both treatment groups
Time Frame: 16-20 weeks of treatment
|
16-20 weeks of treatment
|
At the baseline and the end of study visit the subject will be asked questions for the evaluation of oral allergy syndrome. It is expected that the reduction of oral allergy syndrome complaints will be equal in both treatment groups.
Time Frame: 16-20 weeks of treatment
|
16-20 weeks of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ludger Klimek, PhD, Zentrum für Rhinologie & Allergologie D-Wiesbaden
- Principal Investigator: Oliver Pfaar, MD, Zentrum für Rhinologie & Allergologie D-Wiesbaden
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SB/0027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Birch Pollen Allergy
-
Medical University of ViennaAustrian Science Fund (FWF)CompletedBirch Pollen Allergy | Birch Pollen Related Apple AllergyAustria
-
MacroArray Diagnostics GmbHCompletedCat Allergy | Grass Pollen Allergy | Birch Pollen Allergy | House Dust Mite Allergy | Bee Venom Allergy | Vespid Venom AllergyAustria
-
Desentum OyCompletedBirch Pollen AllergyFinland
-
ALK-Abelló A/SCompletedBirch Pollen AllergyFinland, Netherlands
-
Desentum OyCompleted
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaCompletedAllergic Rhinoconjunctivitis to Birch Pollen | With a Positive Skin Prick Test to Birch PollenFrance
-
AnergisCompletedBirch Pollen AllergySweden, France, Lithuania, Denmark, Latvia, Poland, Switzerland
-
Allergopharma GmbH & Co. KGCompletedBirch Pollen AllergyGermany
-
Allergopharma GmbH & Co. KGCompletedBirch Pollen AllergyGermany
-
Regeneron PharmaceuticalsCompletedHealthy Volunteers | Birch Pollen AllergyBelgium
Clinical Trials on sublingual immunotherapy
-
Zagazig UniversityNot yet recruitingAllergic Rhinitis
-
Zagazig UniversityCompletedEffects of ImmunotherapyEgypt
-
University of GenovaCompletedAllergic Rhinitis (w/w Asthma) Due to Alternaria AlternataItaly
-
Boston Children's HospitalEmory University; Imperial College London; University of Southampton; University... and other collaboratorsNot yet recruiting
-
Stallergenes GreerCompletedPrimary DiseaseFrance, Italy, Spain
-
Stallergenes GreerCompletedAllergic Rhinitis Due to Grass PollensUnited States
-
Stanford UniversityCompletedAsthma | Allergic Rhinitis | AllergiesUnited States
-
University Hospital of CologneCompletedAllergic Rhinitis
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
Casa Espirita Terra de IsmaelFundação de Amparo à Pesquisa do Estado de São PauloCompletedAtopic Dermatitis | Effects of ImmunotherapyBrazil